Ligand Acquires Assets of Novan, Inc. for $12.2 Million
Ligand Offers $15 Million to Acquire Assets of Novan, Inc.
€“ The Company and Ligand Pharmaceuticals sign agreement to sell substantially all of Novans assets under Section 363 of the U.S. Bankruptcy Code, along with a commitment from Ligand to fund $15...
DURHAM, N.C., June 05, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (œthe Company or œNovan) (Nasdaq: NOVN), today announced that it will host a live audio webcast of the Company™s 2023 Annual Meeting of...
Company directing resources on the potential approval of berdazimer gel, 10.3% (SB206) for molluscum contagiosum Process to explore a sale or out-license of commercial assets or other business...
– Continued progress toward PDUFA goal date of January 5, 2024, for berdazimer gel, 10.3% (SB206) – – Strong prescription growth across three promoted products – – Company to host conference call...
DURHAM, N.C., May 08, 2023 (GLOBE NEWSWIRE) -- Novan, Inc. (€œthe Company€ or €œNovan€) (Nasdaq: NOVN), today announced that it will report its first quarter 2023 financial results on Monday, May...
Novan Announces Publication of Psoriasis Patient Data Demonstrating Need for Rapid Symptom Improvement¹
Novan to Host Analyst and Investor Event: A Discussion of Molluscum’s Unmet Need with Pediatric Dermatologist Jeffrey Sugarman, MD, PhD
Novan Reports Full Year 2022 Financial Results and Provides Corporate Update